ifenprodil Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ifenprodil is an inhibitor of the NMDA receptor, specifically of GluN1 and GluN2B subunits. Additionally, ifenprodil inhibits GIRK channels, and interacts with alpha1 adrenergic, serotonin, and sigma receptors.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-2-methyl-1-ethanol | 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol | 61 91 rc | alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine ethanol | ifenprodil | ifenprodil hydrochloride | ifenprodil hydrochloride, (+-)-isomer | ifenprodil, (r*,s*)-(+-)-isomer | ifenprodil tartrate | ifenprodil tartrate (1:1), (r-(r*,r*))-isomer | ifenprodil tartrate (1:1), (r*,s*)-(+-)-(r-(r*,r*))-isomer | ifenprodil tartrate (2:1), (r-(r*,r*))-isomer | ifenprodil, tartrate(r-(r*,r*))-isomer | rc 61-91 | vadilex

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

COVID-19 (Phase 2/Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 2)

Stress Disorders, Post-Traumatic (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue